Seminar “Organisation of Non-Resident’s Activity in Ukraine: Representative Office vs. Legal Entity” Was Presented Jointly by Legal Alliance Law Firm and Innovative Drug Manufacturers’ Association

Business seminar “Organisation of Non-Resident’s Activity in Ukraine:
Representative Office vs. Legal Entity” was held at Legal Alliance offices on March 13.

The event was initiated by the Innovative Drug Manufacturers’ Association.

The seminar was attended by representatives of pharmaceutical companies including Boehringer Ingelheim, Abbott, Novonordisk, Novartis, and Pfizer.

In the course of the seminar, Legal Alliance senior partner Dmitry Aleshko and senior lawyer Andrei Gorbatenko compared pros and contras of acting in Ukraine via a representative office vs. a legal entity, highlighted principal aspects of legal entity constitution form choice, explained tax implications for a representative office compared to a legal entity, and dwelled on organisation of clinical tests via a special purpose company.

Participants of the seminar marked the importance of issues raised in the context of legislative gaps as regards activity of a representative office of a non-resident company in Ukraine.  Of especial interest was the discussion of non resident company office taxation problems remaining of paramount significance for Ukrainian offices of pharmaceutical companies.  Legal Alliance experts presented their analysis of existing regulations concerning likelihood of qualification of representative office activity as business, entailing material tax repercussions.

The informal atmosphere of the event where attendees were free to ask legal questions and receive qualified answers from a qualified lawyer on the spot was a success and the time of the seminar was spent with maximum effect.

All news